Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine and Tamoxifen Interaction Study
NCT01189500Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2010
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of desvenlafaxine in major depressive disorder (MDD) and vasomotor symptoms, sponsored by Pfizer. Primary endpoints: Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) and Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf). Started Aug 2010; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)vasomotor symptoms
Beyond the preview
Go deeper on NCT01189500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189500.